Injectable HDV Basal Insulin for Type 1 and Type 2 Diabetes is under clinical development by Diasome Pharmaceuticals and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Injectable HDV Basal Insulin for Type 1 and Type 2 Diabetes’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Injectable HDV Basal Insulin for Type 1 and Type 2 Diabetes overview
Recombinant peptide (HDV-B) is under development for the treatment of type I and type II diabetes. The drug candidate is administered subcutaneously. HDV-B injectable basal long-acting insulin comprises the intermediate-acting and long-acting versions of injectable HDV-I. It acts by targeting insulin receptor. The drug candidate is developed by using HDV insulin technology using liposomal constructs. HDV-B injectable basal long-acting insulin based on nano-sized insulin carrier that is specifically targeted to hepatocytes, the primary metabolic cells in the liver.
Diasome Pharmaceuticals overview
Diasome Pharmaceuticals (Diasome) is a pharmaceutical company. It focuses on clinical and commercial development of therapies for diabetes and obesity. The company’s pipeline products include multiple injected and oral formulations of liver targeted insulin’s for both type 1 and type 2 diabetic patients. Diasome’s products include oral HDV insulin, injectable HDV insulin and oral HDV candidates among others. The company’s technology platform Hepatocyte directed vesicle (HDV), a cell targeting system which helps to deliver a wide range of necessary hormones and drugs to the liver. It offers products in the fields of insulin replacement, and hepatic (liver) glucose metabolism. Diasome is headquartered in Cleveland, Ohio, the US.
For a complete picture of Injectable HDV Basal Insulin for Type 1 and Type 2 Diabetes’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
